Science & Technology
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AI174328-01
Award Ceiling
$273K
Award Floor
$273K
Close Date
Aug 31, 2024
Total Funding
$273K
Expected Awards
1
Posted Date
Mar 1, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AI174328-01
Description
SBIR Phase Phase I award: "Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection." awarded to Antiger Therapeutics Inc. in SAINT LOUIS, Missouri. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $272,503. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Socially/economically disadvantaged, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.